Chronic Pain - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 335
Inquire Before Buying

Global Markets Direct's, ‘Chronic Pain - Pipeline Review, H2 2016', provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Pain

  • The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects

  • The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Chronic Pain

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Chronic Pain - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Chronic Pain Overview 12
Therapeutics Development 13
Pipeline Products for Chronic Pain - Overview 13
Pipeline Products for Chronic Pain - Comparative Analysis 14
Chronic Pain - Therapeutics under Development by Companies 15
Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22
Chronic Pain - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Chronic Pain - Products under Development by Companies 27
Chronic Pain - Products under Investigation by Universities/Institutes 35
Chronic Pain - Companies Involved in Therapeutics Development 36
AbbVie Inc 36
Acadia Pharmaceuticals Inc. 37
Adynxx, Inc. 38
Allergan Plc 39
Amorsa Therapeutics Inc. 40
arGEN-X BV 41
Asana BioSciences, LLC 42
AskAt Inc. 43
Astraea Therapeutics, LLC 44
Axsome Therapeutics, Inc. 45
BioDelivery Sciences International, Inc. 46
Biogen Inc 47
Bionomics Limited 48
Camurus AB 49
Cara Therapeutics, Inc. 50
Centrexion Therapeutics Corp 51
ChironWells GmbH 52
Collegium Pharmaceutical, Inc. 53
Crinetics Pharmaceuticals, Inc. 54
Cyclenium Pharma, Inc. 55
Cytogel Pharma, LLC 56
Daewoong Pharmaceutical Co., Ltd. 57
Daiichi Sankyo Company, Limited 58
Dompe Farmaceutici S.p.A. 59
Echo Pharmaceuticals B.V. 60
Egalet Corporation 61
Eli Lilly and Company 62
Elite Pharmaceuticals, Inc. 63
Glenmark Pharmaceuticals Ltd. 64
Grunenthal GmbH 65
Heron Therapeutics, Inc. 66
INSYS Therapeutics, Inc. 67
Johnson & Johnson 68
Kareus Therapeutics, SA 69
KPI Therapeutics, Inc. 70
Kymab Limited 71
Laboratorios Del Dr. Esteve S.A. 72
Lohocla Research Corporation 73
Lpath, Inc. 74
MD Biosciences GmbH 75
Merck & Co., Inc. 76
Moberg Pharma AB 77
Mundipharma International Ltd 78
Nanomerics Ltd 79
Nektar Therapeutics 80
Neura Therapeutik, LLC 81
Orion Oyj 82
Pacira Pharmaceuticals, Inc. 83
Pain Therapeutics, Inc. 84
PeriphaGen, Inc. 85
Pfizer Inc. 86
Phosphagenics Limited 87
Prismic Pharmaceuticals, Inc. 88
Purdue Pharma LP 89
Relmada Therapeutics, Inc. 90
Ribomic Inc. 91
Sea4Us 92
Shulov Innovative Science Ltd. 93
Synactix Pharmaceuticals, Inc. 94
Syntrix Biosystems, Inc. 95
Teva Pharmaceutical Industries Ltd. 96
Therapix Biosciences Ltd. 97
Trevena, Inc. 98
Voyager Therapeutics, Inc. 99
Yooyoung Pharmaceutical Co., Ltd. 100
Zynerba Pharmaceuticals, Inc. 101
Chronic Pain - Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Target 104
Assessment by Mechanism of Action 111
Assessment by Route of Administration 118
Assessment by Molecule Type 120
Drug Profiles 122
(celecoxib + tramadol hydrochloride) - Drug Profile 122
(hydrocodone bitartrate + palmidrol) - Drug Profile 124
(morphine sulfate + palmidrol) - Drug Profile 125
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 126
(oxycodone hydrochloride + palmidrol) - Drug Profile 127
(palmidrol + pregabalin) - Drug Profile 128
A-200 - Drug Profile 129
AGN-XX - Drug Profile 130
AGN-YY - Drug Profile 131
AMS-520 - Drug Profile 132
ASN-008 - Drug Profile 133
AVLX-144 - Drug Profile 134
AXS-06 - Drug Profile 135
AYX-1 - Drug Profile 136
AYX-2 - Drug Profile 138
BBI-11008 - Drug Profile 139
bupivacaine - Drug Profile 140
bupivacaine hydrochloride - Drug Profile 142
buprenorphine hydrochloride - Drug Profile 144
buprenorphine hydrochloride depot - Drug Profile 146
buprenorphine hydrochloride ER - Drug Profile 147
buprenorphine hydrochloride long acting - Drug Profile 149
cebranopadol - Drug Profile 150
cetirizine hydrochloride + cromolyn sodium - Drug Profile 153
cetuximab - Drug Profile 154
CNTX-0290 - Drug Profile 160
CNV-3000164 - Drug Profile 161
CNV-3000223 - Drug Profile 162
CR-4056 - Drug Profile 163
CR-701 - Drug Profile 164
CRB-0089 - Drug Profile 165
Cyt-1010 - Drug Profile 166
dexmedetomidine hydrochloride - Drug Profile 168
DF-2593A - Drug Profile 170
difelikefalin - Drug Profile 171
dronabinol - Drug Profile 178
DS-1971 - Drug Profile 180
DWJ-208 - Drug Profile 181
ECP-1014 - Drug Profile 182
Egalet-003 - Drug Profile 183
fluticasone propionate - Drug Profile 184
FY-101C - Drug Profile 185
FY-103B - Drug Profile 186
GBR-900 - Drug Profile 187
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 188
grapiprant - Drug Profile 189
HPI-201 - Drug Profile 191
HS-731 - Drug Profile 192
hydrocodone bitartrate ER - Drug Profile 193
hydrocodone bitartrate ER - Drug Profile 196
hydrocodone bitartrate ER - Drug Profile 197
hydromorphone hydrochloride - Drug Profile 198
Kindolor - Drug Profile 199
KY-1017 - Drug Profile 200
L-779976 - Drug Profile 201
lacosamide - Drug Profile 202
LEVI-04 - Drug Profile 203
levorphanol tartrate ER - Drug Profile 204
Lpathomab - Drug Profile 206
MD-354 - Drug Profile 209
Monoclonal Antibodies for Chronic Pain - Drug Profile 210
Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 211
morphine sulfate ER - Drug Profile 212
MR-309 - Drug Profile 216
NET-END - Drug Profile 218
NKTR-181 - Drug Profile 219
NL-001 - Drug Profile 222
NL-002 - Drug Profile 223
NM-0127 - Drug Profile 224
Omnitram - Drug Profile 225
onabotulinumtoxin A - Drug Profile 226
OSX-300 - Drug Profile 231
OSX-300 Backups - Drug Profile 232
oxycodone hydrochloride ER - Drug Profile 233
oxycodone hydrochloride ER - Drug Profile 236
oxycodone hydrochloride ER - Drug Profile 237
oxymorphone hydrochloride - Drug Profile 239
oxymorphone hydrochloride ER - Drug Profile 240
PAC-CP - Drug Profile 241
palmidrol - Drug Profile 242
Peptide to Block Cav2.2 for CNS Disorders - Drug Profile 243
Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 244
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 245
PN-6047 - Drug Profile 246
PRC-062 - Drug Profile 247
Prostatic Acid Phosphatase - Drug Profile 248
PspTx-3 - Drug Profile 249
raxatrigine hydrochloride - Drug Profile 250
RBM-005 - Drug Profile 253
REL-1017 - Drug Profile 254
SAFit2 - Drug Profile 257
Small Molecule for Chronic Pain - Drug Profile 258
Small Molecule for Chronic Pain - Drug Profile 259
Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile 260
Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile 261
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 262
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 264
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 265
Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 266
Small Molecules for Chronic Wound Pain - Drug Profile 267
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 268
Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile 269
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 270
Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile 271
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 272
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile 273
Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile 274
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 275
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 276
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 277
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 278
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 279
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 280
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 281
Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile 282
Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile 283
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 284
Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile 285
SYN-003 - Drug Profile 286
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 287
tanezumab - Drug Profile 288
tapentadol hydrochloride IR - Drug Profile 291
TRV-734 - Drug Profile 293
U-2902 - Drug Profile 295
UMB-425 - Drug Profile 297
Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile 298
VM-902A - Drug Profile 299
VYNAV-01 - Drug Profile 300
XT-101 - Drug Profile 301
YYC-301 - Drug Profile 302
ZEP-3 - Drug Profile 303
ZYN-001 - Drug Profile 304
Chronic Pain - Dormant Projects 305
Chronic Pain - Discontinued Products 314
Chronic Pain - Product Development Milestones 317
Featured News & Press Releases 317
Appendix 325
Methodology 325
Coverage 325
Secondary Research 325
Primary Research 325
Expert Panel Validation 325
Contact Us 325
Disclaimer 326

List of Tables

Number of Products under Development for Chronic Pain, H2 2016 22
Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 25
Number of Products under Development by Companies, H2 2016 (Contd..1) 26
Number of Products under Development by Companies, H2 2016 (Contd..2) 27
Number of Products under Development by Companies, H2 2016 (Contd..3) 28
Number of Products under Development by Companies, H2 2016 (Contd..4) 29
Number of Products under Development by Companies, H2 2016 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2016 31
Comparative Analysis by Late Stage Development, H2 2016 32
Comparative Analysis by Clinical Stage Development, H2 2016 33
Comparative Analysis by Early Stage Development, H2 2016 34
Comparative Analysis by Unknown Stage Development, H2 2016 35
Products under Development by Companies, H2 2016 36
Products under Development by Companies, H2 2016 (Contd..1) 37
Products under Development by Companies, H2 2016 (Contd..2) 38
Products under Development by Companies, H2 2016 (Contd..3) 39
Products under Development by Companies, H2 2016 (Contd..4) 40
Products under Development by Companies, H2 2016 (Contd..5) 41
Products under Development by Companies, H2 2016 (Contd..6) 42
Products under Development by Companies, H2 2016 (Contd..7) 43
Products under Investigation by Universities/Institutes, H2 2016 44
Chronic Pain - Pipeline by AbbVie Inc, H2 2016 45
Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016 46
Chronic Pain - Pipeline by Adynxx, Inc., H2 2016 47
Chronic Pain - Pipeline by Allergan Plc, H2 2016 48
Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016 49
Chronic Pain - Pipeline by arGEN-X BV, H2 2016 50
Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016 51
Chronic Pain - Pipeline by AskAt Inc., H2 2016 52
Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016 53
Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016 54
Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016 55
Chronic Pain - Pipeline by Biogen Inc, H2 2016 56
Chronic Pain - Pipeline by Bionomics Limited, H2 2016 57
Chronic Pain - Pipeline by Camurus AB, H2 2016 58
Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 59
Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 60
Chronic Pain - Pipeline by ChironWells GmbH, H2 2016 61
Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016 62
Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 63
Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016 64
Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 65
Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 66
Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 67
Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 68
Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016 69
Chronic Pain - Pipeline by Egalet Corporation, H2 2016 70
Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016 71
Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016 72
Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 73
Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016 74
Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016 75
Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016 76
Chronic Pain - Pipeline by Johnson & Johnson, H2 2016 77
Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016 78
Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 79
Chronic Pain - Pipeline by Kymab Limited, H2 2016 80
Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 81
Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016 82
Chronic Pain - Pipeline by Lpath, Inc., H2 2016 83
Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016 84
Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016 85
Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016 86
Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016 87
Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016 88
Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016 89
Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016 90
Chronic Pain - Pipeline by Orion Oyj, H2 2016 91
Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 92
Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016 93
Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016 94
Chronic Pain - Pipeline by Pfizer Inc., H2 2016 95
Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016 96
Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 97
Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016 98
Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 99
Chronic Pain - Pipeline by Ribomic Inc., H2 2016 100
Chronic Pain - Pipeline by Sea4Us, H2 2016 101
Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016 102
Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 103
Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016 104
Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 105
Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016 106
Chronic Pain - Pipeline by Trevena, Inc., H2 2016 107
Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016 108
Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 109
Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 110
Assessment by Monotherapy Products, H2 2016 111
Assessment by Combination Products, H2 2016 112
Number of Products by Stage and Target, H2 2016 114
Number of Products by Stage and Mechanism of Action, H2 2016 121
Number of Products by Stage and Route of Administration, H2 2016 128
Number of Products by Stage and Molecule Type, H2 2016 130
Chronic Pain - Dormant Projects, H2 2016 314
Chronic Pain - Dormant Projects (Contd..1), H2 2016 315
Chronic Pain - Dormant Projects (Contd..2), H2 2016 316
Chronic Pain - Dormant Projects (Contd..3), H2 2016 317
Chronic Pain - Dormant Projects (Contd..4), H2 2016 318
Chronic Pain - Dormant Projects (Contd..5), H2 2016 319
Chronic Pain - Dormant Projects (Contd..6), H2 2016 320
Chronic Pain - Dormant Projects (Contd..7), H2 2016 321
Chronic Pain - Dormant Projects (Contd..8), H2 2016 322
Chronic Pain - Discontinued Products, H2 2016 323
Chronic Pain - Discontinued Products (Contd..1), H2 2016 324
Chronic Pain - Discontinued Products (Contd..2), H2 2016 325

List of Figures

Number of Products under Development for Chronic Pain, H2 2016 22
Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Investigation by Universities/Institutes, H2 2016 31
Comparative Analysis by Late Stage Development, H2 2016 32
Comparative Analysis by Clinical Stage Development, H2 2016 33
Comparative Analysis by Early Stage Products, H2 2016 34
Assessment by Monotherapy Products, H2 2016 111
Assessment by Combination Products, H2 2016 112
Number of Products by Top 10 Targets, H2 2016 113
Number of Products by Stage and Top 10 Targets, H2 2016 113
Number of Products by Top 10 Mechanism of Actions, H2 2016 120
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 120
Number of Products by Top 10 Routes of Administration, H2 2016 127
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 127
Number of Products by Top 10 Molecule Types, H2 2016 129
Number of Products by Stage and Top 10 Molecule Types, H2 2016 129
  • Global Opioids Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Opioids Revenue, means the sales value of Opioids This report studies sales (consumption) of Opioids in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi-aventis - Johnson & Johnson - Teva pharmaceuticals - Purdue Pharma - Pfizer......
  • Global Tramadol Market Research Report 2016
    Published: 25-Nov-2016        Price: US 2900 Onwards        Pages: 118
    Notes: Production, means the output of Tramadol Revenue, means the sales value of Tramadol This report studies Tramadol in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Grnenthal GmbH - Mundipharma - Hexal AG - Labopharm - Pliva Pharma - Nippon Shinyaku......
  • Musculoskeletal Pain-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Musculoskeletal Pain-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Musculoskeletal Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Myalgia-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Myalgia-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Myalgia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, pat......
  • Non Malignant pain-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Non Malignant pain-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Non Malignant pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acute Pain Report is to understand the market and pipeline status of the drugs around the Acute Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipel......
  • Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Fibromyalgia Report is to understand the market and pipeline status of the drugs around the Fibromyalgia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing......
  • Acute Pain-API Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Fibromyalgia-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Fibromyalgia-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Fibromyalgia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fun......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs